If you have been reading about albumin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-13. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
== Advantages over ordinary monoclonal antibodies == Cancer immunotherapy with ordinary monoclonal antibodies does not activate T-lymphocytes because the Fab regions are already used for binding the tumor cells, and this type of cell does not have Fc receptors. Bispecific antibodies also have a higher cytotoxic potential, and bind to antigens that are expressed relatively weakly. The effective dose is around 0.01 mg·m−2·d−1 (milligrams per square meter body surface area per day), which is several orders of magnitude lower than with ordinary antibodies. For non-IgG-like BsAbs, their smaller size allows them to reach antigens usually unavailable to conventional antibodies. In the case of Ebola vaccines, this method allows the antibody to target intracellular targets not usually accessible by traditional monoclonal antibody treatments. Additionally, targeting more than one molecule can be useful to circumvent the regulation of parallel pathways and avoid resistance to the treatment. Binding or blocking multiple targets in a pathway can be beneficial to stopping disease, as most conditions have complicated multifaceted effects throughout the body. Together with combination therapies, BsAbs are being used more and more to treat certain types of cancers, as, over time, some tumors develop resistances to checkpoint inhibitors and/or co-stimulatory molecules.
By increasing farmers' incomes, this could reduce poverty. It would also open up area which farmers could use to diversify crops for household use. The World Bank claims to be part of the solution to malnutrition, asserting that countries can best break the cycle of poverty and malnutrition by building export-led economies, which give them the financial means to buy foodstuffs on the world market. Child malnutrition can worsen with food price inflation. The 2021 to 2023 food price surge is associated with higher rates of wasting among children under five years of age. A 10% increase in food prices is associated with a 2.7% to 4.3% rise in overall wasting and a 4.8 to 6.1 percent increase in severe wasting among children under five years of age.
The first of these incursions occurred when a fleet of these Crusaders was invited by the Portuguese king Afonso I Henriques to conquer the city of Lisbon in 1142. Although this Siege of Lisbon (1142) was a failure it created a precedent for their involvement in Portugal. So in 1147 when another group of Norman and other groups of crusaders from Northern Europe arrived in Porto on their way to join the crusading forces of the Second Crusade, the Bishop of Porto and later Afonso Henriques according to De expugnatione Lyxbonensi convinced them to help with the siege of Lisbon. This time the city was captured and according to the arrangement agreed upon with the Portuguese monarch many of them settled in the newly sacked city. The following year the remainder of the crusading fleet, including a substantial number of Anglo-Normans, was invited by the count of Barcelona, Ramon Berenguer IV, to participate in the siege of Tortosa (1148). Again the Normans were rewarded with lands in the newly conquered frontier city.
Sources: en.wikipedia.org
=== Prosecution in the United States === Following his capture Noriega was transferred to a cell in the Miami federal courthouse, where he was arraigned on the ten charges which the Miami grand jury had returned two years earlier. The trial was delayed until September 1991 over whether Noriega could be tried after his detention as a prisoner of war, the admissibility of evidence and witnesses, and how to pay for Noriega's legal defense. The trial ended in April 1992, when Noriega was convicted on eight of the ten charges of drug trafficking, racketeering, and money laundering. On July 10, 1992, Noriega was sentenced to 40 years in prison. In pre-trial proceedings, the government stated that Noriega had received $322,000 from the U.S. Army and the CIA. Noriega insisted that he had in fact been paid close to $10,000,000, and that he should be allowed to testify about the work he had done for the U.S. government. The district court held that information about the operations in which Noriega had played a part supposedly in return for payment from the U.S. was not relevant to his defense. It ruled that "the tendency of such evidence to confuse the issues before the jury substantially outweighed any probative value it might have had." One of the witnesses in the trial was Carlton, who had previously flown shipments of drugs for Noriega. Information about Noriega's connections to the CIA, including his alleged contact with Bush, were kept out of the trial. After the trial, Noriega appealed this exclusionary ruling by the judge to the Eleventh Circuit Court of Appeals.
== Upholstery filling == Buckwheat hulls are used as filling for a variety of upholstered goods, including pillows. The hulls are durable and do not insulate or reflect heat as much as synthetic filling. They are sometimes marketed as an alternative natural filling to feathers for those allergic to feathers. However, medical studies to measure the health effects of pillows manufactured with unprocessed and uncleaned hulls concluded that such pillows contain higher levels of a potential allergen that may trigger asthma in susceptible individuals than do synthetic-filled pillows.
==== Economy ==== According to Tel Aviv University economist Tomer Fadlon, there would be long-term and significant effects on northern Israel's economy if its population did not return. He further said that even if Israel achieved victory in Gaza, the north would possibly not see an economic recovery. The conflict severely hurt the tourism industry in the north, which employs many people. Many factories in the region have not shut down but suffered labor shortages of up to 50%. According to an estimate by the Bank of Israel in November 2023, the Israeli economy suffers the loss of 590 million shekels ($158 million) every week due absence of work caused by the evacuation of 144,000 people after the Gaza war, 40% of them from the north. Once-robust communities such as Snir and Kiryat Shmona were mostly emptied following the evacuation orders in northern Israel. Kiryat Shmona was planned to be used by food technology businesses, but companies left following the city's evacuation in October 2023. Northern Israel has one-third of Israel's agricultural land, and the occupied Golan Heights and Galilee accounted for 73% of Israel's annual egg production; however, after the outbreak of the conflict, few people remained in the north to tend chicken coops, resulting in a decline in domestic egg production. In August 2024, the Ministry of Agriculture and Food Security approved a quota for the import of 45 million eggs due to the anticipated drop in local production over the conflict and other reasons.
Sources: en.wikipedia.org
Thorium-232 is not fissile, but it can undergo fission with high-energy neutrons. Its use in a reactor fuel cycle requires a fissile driver, such as uranium or plutonium, to sustain a chain reaction. However, 232Th is fertile: it can capture a neutron to form 233Th, which undergoes a beta decay with a half-life of 21.8 minutes to 233Pa, then another with a half-life of 27 days to form fissile 233U. Thorium is estimated to be about three to four times as abundant as uranium in Earth's upper crust. Uranium-233 produced in thorium fuel cycles raises proliferation concerns. Radiation from uranium-232 decay products can complicate fuel handling. The risks depend on fuel-cycle design and safeguards. A 1958 report described the Indian Point reactor under construction, with thorium as a fertile material to supplement uranium-235 fuel. The Shippingport light-water breeder reactor core operated with fuel containing uranium-233 and thorium. Thorium-based nuclear power has not seen large-scale commercial use as of 2024. Nevertheless, some countries such as India have actively pursued thorium-based nuclear power. In November 2025, the Chinese Academy of Sciences reported thorium-to-uranium conversion following thorium loading in an experimental molten-salt reactor built by its Shanghai Institute of Applied Physics and partner institutions. The institute stated that it planned a 100-megawatt demonstration project by 2035.
A study shows most extensively the neuro-molecular mechanics of how a fungal parasite affects behavior of insects. A study found that, of 70,000 monitored species, some 48% are experiencing population declines from human activity, whereas only 3% have increasing populations. By publishing virome-related results, researchers close a major gap in the accumulating research into centenarians' microbiome characteristics for life extension. 16 May – A software tool called Allegro is reported to accurately simulate 44 million atoms, running on the Perlmutter supercomputer. 17 May Astronomers confirm the existence of MACS1149-JD1 (JD1), one of the farthest known galaxies from Earth. Scientists report, based on genetic studies, a more complicated pathway of human evolution than previously understood. According to the studies, humans evolved from different places and times in Africa, instead of from a single location and period of time. The newly discovered exoplanet LP 791-18 d is theorised to be covered with volcanoes, due to the extreme gravitational pull of a super-Earth in the same system. A study proposes school curricula start including useful basic life support, noting that e.g. complemented video lessons could be effective. 18 May Astronomers map the paths of potentially hazardous asteroids for the next 1,000 years. At least 28 asteroids of 1 km diameter or larger are found to have non-zero probabilities of a 'deep encounter' with Earth. A study reports that more than 50% of freshwater lakes and reservoirs lost volume since 1992 due to human and climatic drivers.
Music incorporates types of musical instruments such as the talking drum ensembles, Akan Drum, goje fiddle and koloko lute, court music, including the Akan Seperewa, the Akan atumpan, the Ga kpanlogo styles, and log xylophones used in asonko music. Afro-jazz — "the reuniting of African-American jazz with its African roots" — was created by Kofi Ghanaba. A form of secular music called highlife originated in the 19th and 20th centuries and spread throughout West Africa. In the 1990s, a genre of music was created incorporating the influences of highlife, Afro-reggae, dancehall and hip-hop. This hybrid was called hiplife. There are dances for occasions. Dances for celebrations include the Adowa, Kpanlogo, Azonto, Klama, Agbadza, Borborbor and Bamaya. The Nana Otafrija Pallbearing Services, also known as the Dancing Pallbearers, were featured in a BBC feature story in 2017, and footage from the story became part of an Internet meme in the wake of the COVID-19 pandemic.
=== Mental health and mood disorders === Since the 1950s, over 150 published articles have found a positive outcome in using cranial electrostimulation (CES) to treat depression, anxiety, and insomnia.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.